Independent Data Monitoring Committee Recommends Continuation of Spectrum Pharmaceuticals' Pivotal Registrational Study of Belinostat

Spectrum Pharmaceuticals SPPI announced today that the independent Data Monitoring Committee, per protocol, has performed a safety and futility analysis and has recommended that the pivotal, registrational study for belinostat in relapsed or refractory Peripheral T-Cell Lymphoma, the “BELIEF” Study, continue according to protocol until 100 evaluable patients are enrolled.